Liquid Blister vs Bottle Filling — Which One Wins?

No — they are fundamentally different machines. A blister machine forms cavities from film and seals with foil. A bottle line uses pre-made containers, filling and capping equipment. The dosing pumps are the only commonly shared component. If your portfolio needs both formats, you'll need both lines — though HIJ can deliver them as an integrated turnkey project with shared product preparation (mixing, sterilization) upstream.

Ampoules and vials are technically bottles (rigid pre-formed containers) used for single-dose pharmaceutical liquid. They share blister's single-use advantage but cost 3-8× more per unit due to glass material and complex BFS (blow-fill-seal) machinery. For most non-injectable single-dose oral and ophthalmic liquids, blister offers 70% of the sterility advantage at 20% of the cost. Glass ampoules remain dominant only for injectable parenterals.

Often yes — but it's an opportunity to remove preservatives. If your bottle formulation contains preservatives, parabens, BAK or chelators, you can typically remove them when switching to single-dose blister. This requires a stability study (typically 6-12 weeks accelerated + 12 months real-time) but unlocks "preservative-free" claims that justify +25-40% premium pricing. We can refer you to formulation labs we work with regularly.

The break-even is typically 300K-500K doses per year for premium-positioned SKUs, and 800K-1.2M doses per year for commodity SKUs. Below these thresholds, bottle is cheaper total cost. Above them, blister is cheaper per finished dose despite higher CapEx. We provide a detailed ROI model with every quote — send your projected volumes and we'll run the calculation in 24 hours.

Both can achieve 24-36 month sealed shelf life — that's not the differentiator. The real difference is "in-use shelf life":

• Blister: Single-use means in-use shelf life = 0. The dose is consumed in one event, no degradation possible.
• Bottle: Once opened, in-use shelf life is typically 14-28 days for liquids, 6-8 weeks for thick syrups. Patient adherence drops significantly after this — but no one tracks discarded product.

For products consumed quickly after first open (rinse-out shampoo), this doesn't matter. For products dosed daily over months (vitamins, eye drops), blister's lack of in-use degradation is a major advantage.

Hybrid strategies work well and we recommend them for many categories. The pattern: launch the core SKU in a bottle for the price-sensitive bulk channel, then extend the brand with a premium blister line for travel/sample/clinical channels. Robitussin, Theraflu, and most major OTC brands do this. The blister extension typically commands 2-3× higher gross margin per dose and reaches different shopper segments.

Bottles are absolutely not obsolete — they remain the right format for many applications. Most current pharmacy bottle products are legacy SKUs launched 20-40 years ago when blister technology was less mature. As patents expire and brands relaunch with "improved" positioning, many are shifting to unit-dose blister to refresh the line. We're not anti-bottle. We're pro-fit-for-purpose. For a daily-use 200ml syrup, bottle is correct. For a pediatric antibiotic course of 14 doses, blister is correct. Match format to actual use case.

HIJ specializes in liquid blister packaging — that's our core competency, with 20+ years of engineering depth and 200+ customer installations. For bottle filling, we provide turnkey integration through our partner network. If you need only a bottle line, we'll honestly refer you to specialist suppliers. If you need a blister line — that's what we build, better than anyone in our segment. See our liquid blister machine range →